Proprietary peptide technology platform to develop oral targeted therapy-based drugs and injectables for rare diseases. PTG-300 injectable hepcidin mimetic Ph 2 trials ongoing in polycythemia vera and hereditary hemochromatosis; updated Phase 2 results in PV expected by YE 2020. PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis to begin early 2020; PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist Ph 2 Crohn’s disease study ongoing.
US - Pacific
Phase l or ll
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
500MM - 1B
521 Cottonwood Drive
Milpitas, CA 95035
Top 10 Holders of Protagonist Therapeutics, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by